Drug Discovery World

OCTOBER 13, 2022

There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. . Over the two days at ExCel, 1554 delegates attended the event. Read more on the programme here.

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

MAY 25, 2023

The company uses donated cells from patients and iPSC technology to build physiologically relevant in vitro models, with a special focus on neurodegenerative diseases like Alzheimer’s disease. It also hopes to optimise production, archiving and sharing of mouse model data, following the principles of the three Rs: reduce, reuse, recycle.

Research 52

Research Drugs In-Vitro Insulin 52

XTalks

OCTOBER 12, 2022

MRI may also be used to evaluate drug dosing regimens, to gain insight about the mechanism of drug action, and to collect imaging biomarker data which could provide an earlier indication of response to therapy than clinical outcomes. Each patient is represented as one data point. Why Image Vascular Perfusion? Figure from Ricart et al.,

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93

Drug Discovery World

AUGUST 10, 2022

Fortunately, because all these elements can be tracked by detecting and quantifying nucleic acids, manufacturers can assess the safety using Droplet Digital PCR (ddPCR) technology. How ddPCR technology detects and quantifies DNA ddPCR technology is a highly sensitive and accurate tool used to detect and quantify known genetic sequences.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

The Pharma Data

NOVEMBER 9, 2020

Additionally, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data). First Results.

Immune Response 40

Immune Response Containment Trials Clinical Trials 40

XTalks

AUGUST 17, 2020

In this way, the platform allows for the generation of a vast number of therapeutic molecules from a very well formatted platform, which is the core strength of the technology. The study commenced in September 2019 (NCT03978689) and interim data is expected later this year. Targeting HPV-Induced Head and Neck Cancer.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Pharmaceutical Technology

JUNE 26, 2022

As every molecule and development program is unique, there is no single drug substance synthesis and manufacturing solution, so understanding what processes and technologies are available, what strategy is best, and who to partner with is key. . Applying real-time data. Important considerations for drug substance development.

Manufacturing 130

Manufacturing Drugs Production Development 130

Drug Discovery World

FEBRUARY 27, 2023

It has applications for major detection technologies, including fluorescence intensity, fluorescence polarisation, absorbance, luminescence and time-resolved fluorescence (TRF). It supports the incorporation of replicates, controls and seven-point dose-response curves to improve data robustness and reproducibility.

Drugs 52

Drugs Life Science Protein Scientist 52

The Pharma Data

MARCH 26, 2021

The FDA EUA submission is based on an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial, which evaluated VIR-7831 as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalisation.

Antibody 52

Antibody Trials Vaccination Vaccine 52

The Pharma Data

MAY 7, 2021

The EMA will evaluate all data on sotrovimab, including evidence from clinical trials, as they become available. The review of the data is being carried out by the EMA’s Committee for Medicinal Products for Human Use (CHMP). GSK and Vir continue discussions with global regulators to make sotrovimab available to patients with COVID-19.

Antibody 52

Antibody Trials Vaccination Vaccine 52

Roots Analysis

MARCH 24, 2022

It leverages understanding of a diverse set of metabolic enzymes, their kinetics, end products, and the known biochemical pathways in which the set of metabolites participate. Therefore, further studies are required to re-analyze the generated data. Unknown Metabolite Identification. Our Social Media Platform. Web: [link].

Clinical Research 52

Clinical Research Development Research Drug Delivery Systems 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. He will discuss selection technologies for membrane targets using advances in whole cell panning and comparative deep sequencing.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

AUGUST 1, 2021

At the Digestive Disease Week (DDW) Virtual Conference 2021 and the Congress of European Crohn’s and Colitis Organisation (ECCO), AbbVie presented data from a broad range of studies in inflammatory bowel diseases (IBD). years in patients with RA. years in patients with RA.

Botox 52

Botox Cosmetics Trials Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.

Licensing 52

Licensing Licensing Protein Antibody 52

Drug Discovery World

JULY 25, 2022

Our recent data in Figure 2B, illustrates that binding to one of our hit series interferes with the interaction between the two proteins, with a significant increase in the abundance of GSDMD monomer, which is bound to our hit. The screen has already been successfully applied to GSDMD and has yielded several credible hits. About the authors.

Drugs 52

Drugs Protein Life Science Genetics 52

The Pharma Data

APRIL 27, 2021

“We are excited to present a range of data that will help us better understand not just how our portfolio performs in the clinic, but also the real-world experiences of our patients,” said Michael R. . Food and Drug Administration based on data from the Phase 3 GEMINI 1 and GEMINI 2 clinical studies. NORTH CHICAGO, Ill.

Research 40

Research Drug Delivery Systems Drug Delivery Production 40